Last reviewed · How we verify

NCT00802451

A Study to Evaluate the Relative Bioavailability of Two Mesalamine 4 gm/60 ml Rectal Enema Formulations

Completed NA Last updated 7 October 2021
What this trial tests

NA trial testing Mesalamine in Healthy in 48 participants. Completed in 1 March 2003.

Timeline
1 February 2003
Primary endpoint
1 March 2003
1 March 2003

Quick facts

Lead sponsorPadagis LLC
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment48
Start date1 February 2003
Primary completion1 March 2003
Estimated completion1 March 2003

Drugs / interventions tested

Conditions studied

Sponsor

Padagis LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate the relative bioavailability of the test formulation of mesalamine suspension rectal enema with the reference formulation in healthy, adult subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Mesalamine

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Padagis LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00802451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing